We are live on ! Find out more
OCS icon

Oculis Holding

7 hedge funds and large institutions have $23.2M invested in Oculis Holding in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

9.54% more ownership

Funds ownership: 0%9.54% (+9.5%)

Holders
7
Holders Change
+7
Holders Change %
% of All Funds
0.11%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
7
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
PBPIA
1
Pivotal bioVenture Partners Investment Advisor
California
$17.7M +$19.9M +2,381,196 New
NFGH
2
Nan Fung Group Holdings
Hong Kong
$4.84M +$5.45M +651,100 New
CLOS
3
Compagnie Lombard Odier SCmA
Switzerland
$472K +$544K +65,000 New
HF
4
HRT Financial
New York
$178K +$206K +24,609 New
UBS Group
5
UBS Group
Switzerland
$9.01K +$10.1K +1,212 New
EC
6
Elequin Capital
New York
$2.23K +$2.51K +300 New
DCM
7
Dupont Capital Management
Delaware
$29 +$33 +4 New

OCS Hedge Fund Activity: Q1 2023 in Review

7 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Oculis Holding (OCS) for Q1 2023, worth a combined $23.2M.

Buyers outnumbered sellers: 7 funds opened new OCS positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Pivotal bioVenture Partners Investment Advisor, opening a new position worth an estimated $19.9M.

  • 7 institutional investors held Oculis Holding (OCS) as of Q1 2023, up from 0 in Q4 2022.
  • Funds reported $23.2M of Oculis Holding stock for Q1 2023.
  • 7 funds opened new Oculis Holding positions in Q1 2023 and 0 closed out, a net change of +7 holders.
  • The largest Oculis Holding buyer in Q1 2023 was Pivotal bioVenture Partners Investment Advisor, an estimated $19.9M added.

Based on aggregated 13F filings for Q1 2023.